Growth of 28% of 2024 first quarter revenue
April 16 2024 - 2:00PM
Growth of 28% of 2024 first quarter revenue
Press
release Ecully,
April 16, 2024 – 8 p.m.
First-quarter 2024 revenue of €3.1
million Growth of 28% compared with 2023 first
quarter
In thousands of euros |
2024 |
2023 |
Change 2023/2022 |
Q1 revenue |
3,070 |
2,398 |
+28% |
Unaudited consolidated data
Spineway, a specialist in innovative implants
for the treatment of severe spine disorders, recorded revenue of
€3.1 million in the first quarter of 2024, an increase of 28%
compared with the same period in 2023.
This purely organic growth (with no scope
effect) reflects the Group’s strong sales momentum in its two main
regions, Europe and Latin America, which accounted for 85% of
revenue over the quarter. This growth was driven by sales of
premium ranges (especially VEOS - Distimp).
Europe (58% of revenue)
continued to grow, driven by sales of Distimp and Spine Innovations
products, particularly in France. Quarterly revenue came to €1.8
million, compared with €1.4 million as of 2023 first quarter (up
28%), demonstrating the continued strengthening of the Group’s
sales in this area.
Over the period, sales in Latin
America (27% of total revenue) rose to €0.8 million from
€0.3 million in the same period in 2023. This was driven by higher
sales of the Spineway range and sales of Spine Innovations range in
Mexico.
The positive revenue trend for the first
quarter of 2024 confirms Spineway’s ability to gain market share
and grow in an increasingly demanding environment. This sales
growth will enable the Group to continue its investments to obtain
new approvals and CE/MDR certifications for its product ranges. The
Group confirms its aim of becoming a major player in less invasive
spine treatments.
Next event:July 17, 2024
– H1 2024 revenue
SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY
SAVINGS PLANS FOR SMES)Find out all about Spineway at
www.spineway.com
This press release has been prepared in both
English and French. In case of discrepancies, the French version
shall prevail.
Spineway
designs, manufactures and markets innovative implants and surgical
instruments for treating severe disorders of the spinal
column.Spineway has an international network of
over 50 independent distributors and more than 70% of its revenue
comes from exports.ISIN: FR001400BVK2 –
ALSPW
Contacts:
SPINEWAY GROUPShareholder-services lineAvailable
Tuesday through Thursday+33 (0)806 706 060 |
Eligible PEA / PMEALSPWEuronext Growth |
AELIUMFinance & CommunicationInvestor
relationsSolène Kennisspineway@aelium.fr |